Relmada Therapeutics Inc

NASDAQ:RLMD  
33.85
+0.35 (+1.04%)
Earnings Announcements

Relmada Therapeutics Reports Q4 Loss Per Share $1.28

Published: 03/23/2021 21:07 GMT
Relmada Therapeutics Inc (RLMD) - Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-year 2020 Financial Results.
Q4 Loss per Share $1.28.
Q4 Earnings per Share Estimate $-1.16 -- Refinitiv Ibes Data (analyst estimates).
Relmada Therapeutics - As of Dec 31, 2020, Had About $117.1 in Cash, Equivalents, Short-term Investments.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.48

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.49

More details on our Analysts Page.